A5069673526- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Cancer Research and Treatments
- Virology and Viral Diseases
- Brain Metastases and Treatment
- Ocular Oncology and Treatments
- Animal Virus Infections Studies
- Glioma Diagnosis and Treatment
- Kruppel-like factors research
- Hemoglobinopathies and Related Disorders
- Melanoma and MAPK Pathways
- Polyomavirus and related diseases
- Acute Myeloid Leukemia Research
- Vascular Malformations Diagnosis and Treatment
- CRISPR and Genetic Engineering
- Biotechnology and Related Fields
- Medical Imaging and Pathology Studies
- Immune Response and Inflammation
- Cancer, Stress, Anesthesia, and Immune Response
- Chemokine receptors and signaling
- Soft tissue tumors and treatment
- Full-Duplex Wireless Communications
University of Minnesota
2016-2025
Allina Health
2024
University of Minnesota Medical Center
2008-2023
Masonic Cancer Center
2018-2023
Mayo Clinic in Arizona
2012-2022
University of Minnesota System
2018
Mayo Clinic
2009-2017
The University of Western Australia
2011
Centro de Biología Molecular Severo Ochoa
2011
Universidad Autónoma de Madrid
2011
Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes has demonstrated efficacy in melanoma. Lifileucel is an autologous, centrally manufactured lymphocyte product.We conducted a phase II open-label, single-arm, multicenter study had been previously treated inhibitor(s) BRAF ± MEK agents. was produced from...
Five cases of axillary lymphadenopathy are presented, which occurred after COVID-19 vaccination and mimicked metastasis in a vulnerable oncologic patient group. Initial radiologic diagnosis raised concerns for metastasis. However, further investigation revealed that patients received vaccinations the ipsilateral arm prior to imaging. In two cases, lymph node biopsy results confirmed vaccination-related reactive lymphadenopathy. Ipsilateral swelling or was reported based on symptoms physical...
Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 patients who progressed ICI and targeted therapy. Herein, we report independent review committee (IRC)-assessed outcomes 153 treated lifileucel large multicenter Phase 2 therapy trial melanoma.Eligible had that...
Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable drive robust pathologic responses. In NeoACTIVATE (NCT03554083), a Phase II trial, patients with clinically evident resectable melanoma received either 12 weeks neoadjuvant vemurafenib, cobimetinib, atezolizumab (BRAF-mutated, Cohort A, n = 15), or cobimetinib...
Sebaceous carcinoma is an aggressive adnexal skin tumor with a predilection for the eyelids and sebaceous glands of head neck.A 73 year-old man presented confusion was found to have widely disseminated metastases brain, lungs, liver, bowel, lymph nodes, bone. Following initial treatment brain surgery he received post-operative radiosurgery. He then began systemic immunotherapy pembrolizumab. After 6 months, developed near complete response therapy by irRECIST RECIST v.1.1. The associated...
10006 Background: Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) leverages enhances the body’s natural defense against cancer has shown durable responses in heavily pretreated patients. Methods: C-144-01 is a global Phase 2 open-label, multicenter study of efficacy & safety lifileucel unresectable metastatic BRAF/MEK inhibitors, if BRAF...
Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological response rates, while immunotherapy regimens show favorable recurrence-free survival (RFS). NeoACTIVATE was designed to address whether a neoadjuvant combination of both targeted and might leverage benefits each. Methods We tested 12 weeks vemurafenib, cobimetinib, atezolizumab BRAF-mutated...
Abstract Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses immune checkpoint therapies. Prior research suggests that MBM poor tumor enriched in oxidative phosphorylation. Here, we report results from a multi-omic analysis of large, real-world melanoma cohort. exhibited lower interferon-gamma (IFNγ) scores T cell-inflamed compared primary cutaneous (PCM) or extracranial (ECM), which was independent mutational burden. Among MBM, there were fewer...
9505 Background: Immune checkpoint inhibitors (ICI) have become standard of care for treatment metastatic melanoma. Most patients with advanced melanoma progress on ICI and options are limited these patients. Progression may be through primary resistance (lack response) or secondary (initial response then progression). Lifileucel is an adoptive cell therapy using TIL, that has shown efficacy in who on/after anti-PD-1 (Sarnaik, 2020). We present the 28-month (mos) follow-up data highlight...
Abstract Purpose: Mucosal melanoma is a rare, aggressive form of with extremely high recurrence rates despite definitive surgical resection curative intent. Currently there no consensus on adjuvant therapy. Data checkpoint inhibitors for therapy are lacking. Patients and Methods: We performed single-arm, multicenter clinical trial using “flip dose” ipilimumab (1 mg/kg q3w × 4 cycles), nivolumab (3 then 480 mg q4w 11 cycles to complete year Participants must have had R0/R1 ≤90 days before...
26 Background: NKTR-262 is a novel intratumoral prodrug designed to promote tumor antigen release, an immune stimulatory environment, and presentation. NKTR-214 increases CD8+ T cells NK in the microenvironment. The combination of with accesses innate adaptive immunity provide abscopal response systemic immunity. Phase 1b/2 REVEAL trial enrolling. Methods: In 3+3 1 design, pts who are relapsed/refractory ≥1 CPI receive escalating doses (IT) followed by combined q3w treatment IT fixed-dose...
Altered inflammation signaling within the cerebral vasculature may be an important risk factor for stroke in children with sickle cell anemia (SCA). This study examines how differential expression of NFkappaB/p65 (RelA), KLF2, and other transcription factors act as switches leading to observed differences between non-SCA (NS) African Americans SCA who are either at (AR) or not (NAR) childhood based on occurrence Circle Willis disease. Clover/Transfac analysis was used identify...
Abstract Lessons Learned Percutaneous thermal ablation combined with in situ granulocyte-macrophage colony-stimulating factor cytokine therapy was technically feasible and well tolerated. No significant clinical or immunologic responses were seen. Background Melanoma tumor-derived heat-shock proteins (HSPs) HSP-peptide complexes can elicit protective antitumor responses. The (GM-CSF) chemokine also promote uptake processing by professional antigen presenting cells (APCs). On this basis, we...
<h3>Background</h3> NKTR-262 is a small-molecule agonist of toll-like receptors (TLR) 7/8. Given by intratumoral (IT) injection, retained within the tumor microenvironment (TME) and promotes an immunostimulatory milieu antigen release. Bempegaldesleukin (BEMPEG) CD122-preferential IL-2 pathway agonist, which increases proliferation infiltration CD8<sup>+</sup> T cells natural killer (NK) cells. Preclinically, plus BEMPEG combined innate immune signaling enhanced presentation, with sustained...
<h3>Background</h3> Immune checkpoint inhibitors (ICI) have improved outcomes for patients with metastatic melanoma; nevertheless, resistance is common and subsequent treatment options are limited. Lifileucel, a one-time autologous TIL cell therapy, achieved 31.4% objective response rate (ORR) median duration of (DOR) not reached at 36.5 months follow-up, in advanced (unresectable or metastatic) melanoma who progressed after ICI targeted therapy (if appropriate; Sarnaik SITC 2022). We report...
Introduction Metastatic uveal melanoma (mUM) is a difficult to treat disease. The liver the primary site of metastasis in most patients, though spreads widely advanced only FDA approved immunotherapy medication for metastatic HLA-A02:01 restricted bispecific T cell engager drug, Tebentafusp. Checkpoint inhibitor strategies and combination approaches have been tried with some limited success. We describe our experience treating patients at University Minnesota. Methods Patients were included...
BAP-1 (BRCA1-associated protein 1) inactivated melanocytic lesions are a group of familial or sporadic with unique histology and molecular features. They great clinical interest, at least in part due to the potential for malignant transformation association cancer predisposition syndrome. Here, we describe patient multiple spatially temporally distinct loss BAP1 expression by immunohistochemistry. RNA sequencing was performed on three independent spanning morphologic spectrum: benign nevus,...
Myoepithelioma of the soft tissues is a rare entity and little known about how best to manage locally recurrent high-grade disease. Here, we retrospectively examined outcomes surgery, chemotherapy, radiation therapy (RT) for treatment low-grade myoepithelioma tissues.We reviewed 20 cases seen at Mayo Clinic between 1994 2014. The effect histologic grade therapies received on relapse survival were assessed.We identified 13 patients with disease 7 We found that was frequently effectively...